{"id":2361,"date":"2014-09-19T11:54:54","date_gmt":"2014-09-19T11:54:54","guid":{"rendered":"https:\/\/medicalcriteria.com\/web\/onckho\/"},"modified":"2026-04-08T20:13:38","modified_gmt":"2026-04-08T20:13:38","slug":"onckho","status":"publish","type":"post","link":"https:\/\/medicalcriteria.com\/web\/es\/onckho\/","title":{"rendered":"Score de Khorana para la Predicci\u00f3n de Eventos Tromboemb\u00f3licos Venosos (TEV) en Pacientes con C\u00e1ncer"},"content":{"rendered":"<div class=\"7ca9444b8380138fe077da07353677a4\" data-index=\"1\" style=\"float: none; margin:0px 0 0px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- MC 2019- Horizontal -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-0127150553352455\"\r\n     data-ad-slot=\"3806776041\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p>Las herramientas de evaluaci\u00f3n de riesgo pueden incorporar m\u00faltiples variables para identificar a pacientes o subpoblaciones en riesgo de eventos. Una puntuaci\u00f3n de riesgo desarrollado recientemente puede identificar a los pacientes con c\u00e1ncer con alto riesgo de tromboembolismo venoso (TEV)\u00a0utilizando una combinaci\u00f3n de variables cl\u00ednicas y de laboratorio f\u00e1cilmente disponibles.<br \/>\n<!--more--><br \/>\n<strong>Score de Riesgo Modificado de Khorana para la Predicci\u00f3n de Eventos Tromboemb\u00f3licos Venosos (TEV) en Pacientes con C\u00e1ncer<\/strong><\/p>\n<table style=\"border-collapse: collapse; width: 100%; height: 192px;\" border=\"1\">\n<tbody>\n<tr style=\"height: 24px;\" valign=\"TOP\">\n<td style=\"height: 24px;\" width=\"467\"><strong>Caracter\u00edstica del Paciente<\/strong><\/td>\n<td style=\"text-align: center; height: 24px;\" width=\"158\"><strong>Puntos<\/strong><\/td>\n<\/tr>\n<tr style=\"height: 24px;\" valign=\"TOP\">\n<td style=\"height: 24px;\" width=\"467\">Sitio de c\u00e1ncer: Riesgo muy alto (est\u00f3mago, p\u00e1ncreas, tumor cerebral primario)<\/td>\n<td style=\"text-align: center; height: 24px;\" width=\"158\">2<\/td>\n<\/tr>\n<tr style=\"height: 48px;\" valign=\"TOP\">\n<td style=\"height: 48px;\" width=\"467\">Sitio de c\u00e1ncer: alto riesgo (pulm\u00f3n, linfoma, ginecol\u00f3gico, vejiga, test\u00edculos, tumores renales)<\/td>\n<td style=\"text-align: center; height: 48px;\" width=\"158\">1<\/td>\n<\/tr>\n<tr style=\"height: 24px;\" valign=\"TOP\">\n<td style=\"height: 24px;\" width=\"467\">Recuento de plaquetas pre-quimioterapia 350.000\/\u00b5L o m\u00e1s<\/td>\n<td style=\"text-align: center; height: 24px;\" width=\"158\">1<\/td>\n<\/tr>\n<tr style=\"height: 24px;\" valign=\"TOP\">\n<td style=\"height: 24px;\" width=\"467\">Nivel de hemoglobina &lt;10 g\/dl o uso de factores de crecimiento de gl\u00f3bulos rojos<\/td>\n<td style=\"text-align: center; height: 24px;\" width=\"158\">1<\/td>\n<\/tr>\n<tr style=\"height: 24px;\" valign=\"TOP\">\n<td style=\"height: 24px;\" width=\"467\">Recuento de leucocitos pre-quimioterapia &gt;11.000\/\u00b5L<\/td>\n<td style=\"text-align: center; height: 24px;\" width=\"158\">1<\/td>\n<\/tr>\n<tr style=\"height: 24px;\" valign=\"TOP\">\n<td style=\"height: 24px;\" width=\"467\">\u00cdndice de masa corporal de 35 kg\/m2 o m\u00e1s<\/td>\n<td style=\"text-align: center; height: 24px;\" width=\"158\">1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Calcular la puntuaci\u00f3n total, sumando puntos para cada criterio en el modelo.<br \/>\nInterpretaci\u00f3n:<\/p>\n<ul>\n<li>Alto riesgo &gt;\/= 3 puntos<\/li>\n<li>Riesgo intermedio, de 1 a 2 puntos<\/li>\n<li>Bajo riesgo, 0 puntos<\/li>\n<\/ul>\n<p>Abreviatura: TEV, tromboembolismo venoso.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Bibliograf\u00eda:<\/strong><\/p>\n<ol>\n<li>Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A; American Society of Clinical Oncology Clinical Practice.\u00a0Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10;31(17):2189-204.\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23669224\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Khorana AA, McCrae KR. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res. 2014 May;133 Suppl 2:S35-8. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24862143\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Gomes M, Khorana AA. Risk assessment for thrombosis in cancer. Semin Thromb Hemost. 2014 Apr;40(3):319-24.\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24599438\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Fowler C, Pastores SM. Venous Thromboembolic Events in Cancer Immunotherapy: A Narrative Review. J Clin Med. 2025 Jul 11;14(14):4926. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40725619\/\" target=\"_blank\" rel=\"noopener\">[Medline]<\/a><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p>Creado Sep 19, 2014.<br \/>\nActualizado Abr 08, 2026.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Las herramientas de evaluaci\u00f3n de riesgo pueden incorporar m\u00faltiples variables para identificar a pacientes o subpoblaciones en riesgo de eventos. Una puntuaci\u00f3n de riesgo desarrollado recientemente puede identificar a los pacientes con c\u00e1ncer con alto riesgo de tromboembolismo venoso (TEV)\u00a0utilizando una combinaci\u00f3n de variables cl\u00ednicas y de laboratorio f\u00e1cilmente disponibles.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"no","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[272],"tags":[896,897,669,428,767,450,898,899],"class_list":["post-2361","post","type-post","status-publish","format-standard","hentry","category-oncology","tag-events","tag-khorana","tag-modified","tag-prediction","tag-risk","tag-score","tag-thromboembolic","tag-venous"],"modified_by":"Guillermo Firman","_links":{"self":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/comments?post=2361"}],"version-history":[{"count":5,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2361\/revisions"}],"predecessor-version":[{"id":10738,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2361\/revisions\/10738"}],"wp:attachment":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/media?parent=2361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/categories?post=2361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/tags?post=2361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}